Embecta stock
EMBCNASDAQEmbecta Corp., HealthcareISIN US29082K1051
63Score 63 out of 100, Neutral
Price and trend
61 / 100
Price history
−56% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.7% above it.
Since January 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 56% below its 52-week high. Largest decline in 5 years: 94% (March 2022 to May 2026).
Chart figures for advanced users
- SMA 50$5.95
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.20
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.90
- The lowest closing price of the last twelve months.
- Resistance$14.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Embecta Corp. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $364.32M, is number 43 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.08B (down 3.8% year on year) and earnings of $95.4M (up 21.8%).
- For fiscal 2026, analysts expect on average revenue of $1.02B (down 5.4%) and adjusted earnings per share of $1.84 (down 38.2%).
Show more
- MEQIRI Score 63 out of 100 (Neutral): rank 234 of 714 in Healthcare, median 53.
- The P/E is 4.3 (Medical (Instruments & Supplies) median 34.8, own median of recent years 9.6).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 4.3, Medical (Instruments & Supplies) median 34.8, own median 9.6.Valuation 100
- High return on capitalReturn on invested capital 39.9% in fiscal 2025, Medical (Instruments & Supplies) median 5.4%.Profitability 79
- Earnings turn into cashFree cash flow 188% of earnings over the last 12 months.Fundamentals 100
Weaknesses
- Earnings per share fallingDown 26.2% a year since 2020.Growth 12
- Share price fell sharplyDown 55% over the last 12 months.Momentum 55
- Volatile share priceVolatility 82% a year over the last 12 months.Stability 36
Its standout strengths are fundamentals and valuation, while stability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
What lowers it
- solid fundamentals
- low growth grade (crashed less often in the backtest)
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Possible value trap: looks cheap, but high risk, weak growth.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 7.6% on the twelve months before. Revenue has stayed largely stable since 2019.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 63%, operating 30%, net 9%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Nov 2026in 12 days
- Last reported
- 7 Aug 2026EPS reported $0.56 (expected $0.27)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.760.0%
- Revenue
- $1.07B0.0%
- Earnings per share
- $1.950.0%
- Revenue
- $1.09B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +42.6%Adjusted operating margin guidance raised to 23.5% to 24% (from 22.25% to 23.25%) and adjusted EPS to $1.80 to $1.90 (from $1.55 to $1.75); revenue guidance of $1.015 to $1.035 billion reaffirmed.
“In terms of adjusted operating margin, we are raising our adjusted operating margin guidance from a range of between 22.25% and 23.25% to a new range of between 23.5% and 24%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
4 insiders bought on the open market between 12 Aug 2026 and 12 Aug 2026, $557,945 in total. One insider sold, $36,971 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Embecta
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 63
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- SKAN GroupSKAN.SW $1.88B72
- LeMaitre VascularLMAT $1.81B70
- STAAR SurgicalSTAA $1.34B45
- GerresheimerGXI.DE $1.23B48
- Safilo GroupSFL.MI $952.24M61
- Dynavox GroupDYVOX.ST $784.94M66
- AngioDynamicsANGO $522.32M40
- COLTENE HoldingCLTN.SW $344.54M61
ETFs that hold Embecta
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 0.03% | 0.35% | €204.34M |
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 0.03% | 0.29% | €182.46M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Show 1 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Mar 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.